BioSciKin competition for life sciences start-ups (audience registration started)

Date: April 7, 2016 @ 6:00 pm – @ 10:40 pm
Location: Stanford University, Room130, Li Ka Shing Learning and Knowledge Center, 291 Campus Drive, Stanford, CA 94305 (map at the bottom, light dinner provided)

San Francisco Bay Area Startup Competition Preliminary in Life Science

If interested in participating in the competition, please go to CLICK HERE TO APPLY under "how to participate".  The application deadline is March 15, 2016  

If interested to be an audience, please go to REGISTER at the top or bottom.

For more information, please email BSK’s US contact at

Nanjing BioSciKin Co., Ltd (BSK), an open investment and incubation platform in China for life science innovation is sponsoring an international startup contest in life science. The co-sponsors include influential Chinese industrial investors, pharmaceutical companies and Chinese media with the support of a powerful alliance of strategic investors. The event runs from December 2015 to June 2016. It will take place in 8 cities in both China and the US, where the US preliminaries will be held in San Francisco and Boston. The final competition will be in Shanghai.


• Your BP will be exposed to many investment firms including BSK, Hony Capital, Fosun Pharma, Trust Bridge Partners, Ally Bridge Group, GT Capital, PointGuard Ventures, Bohe Ventures, Tenyall Investment, Firestone Investing, Spruce Capital Partners and BAR Capital Management.

• The investment can be in the US or China. It is not mandatory to set up China presence. The above firms have invested in many life science companies in the US and China.

• The investment can be, but not limited to, $500K to $10 million.

• All BPs submitted before deadline of March 15, 2016 will get feedback by email from judges and investment firms. If your BP receives good reviews, you will have meeting with investment firms.

• 1st place company in each preliminary will receive $30,000 in non-dilutive financing. 1st and 2nd place companies in each preliminary will receive a paid trip to Shanghai to present at the final in front of many investors.

Who can participate: The event welcomes both companies and entrepreneurial teams in life science area.

How to participate:

  1. Application Deadline is March 15, 2016: please send an executive summary or no more than 10 slides in either PowerPoint or as a PDF along with your contact information below.

  2. About 10 startups will be selected to showcase their projects at preliminaries.  You will receive a formal invitation to the preliminaries.  Two teams with the highest ratings from the judge panel will advance to the final.

For more information, please email BSK’s US contact at






Open remarks

Lecture by keynote speaker:

“Noninvasive liquid biopsy for cancer patient”



Dr. Lin Wu


Project road show part I

(10 mins presentation; 5 mins Q&A each)

5 contestants


Tea break


Project road show part II

(10 mins presentation; 5 mins Q&A each)

5 contestants


Announcement of preliminary results and prize presentation

The sponsors, judge panel

Keynote Speaker:

Dr. Lin Wu

Dr Lin Wu is Vice President, Development for the Sequencing Business Unit of Roche Diagnostics. Dr. Wu has strong background in IVD assay development and registration. She led the development of the first microarray-based pharmacogenetic assay approved by the FDA, AmpliChip CYP450, and assumed various leadership roles during the development of the cobas oncology portfolio. Dr. Wu pioneered the scientific research work in detecting tumor DNA in blood, which eventually led the launch of cobas EGFR blood assay. This work was the first recipient of Roche Diagnostic DIAmond Award for R&D Innovation.Dr. Lin Wu received her Ph. D. in Molecular Biology from State University of New York at Buffalo. Prior joining Roche, she completed her post-doctoral fellowship in cancer biology at Princeton University.

Panel of Judges:

Pete Thomas

Pete Thomas is a Managing Director of PointGuard Ventures(PGV). Prior to co-founding PointGuard Ventures, Pete co-founded ATA Ventures in 2004, a firm that raised $440M in capital across three funds during the last ten years. ATA has invested in over 40 early stage companies and Pete was on the board and directly involved in 11 of those companies and is presently on the board of Revera, Lavante, and Adesto Technologies and is an advisor to Theranos.

Krish Panu

Kris panu is a Managing Director of PointGuard Ventures(PGV). For more than two decades Krish has built successful technology businesses which have created multi-billion dollar markets. Prior to entering the venture capital industry, Krish has held executive positions in several influential companies including @Road, Inc., Atmel, Catalyst Semiconductor, Datapoint Corporation and Xicor etc.

Roger Wyse

Dr.  Roger Wyse is the Managing Partner of Spruce Capital Partners and BAR Capital Management. He chairs or serves on the boards of 11 private companies. He is Co-Chairman of the $162M Malaysian Life Sciences Capital Fund. Heis also an internationally recognized scientist and was a Dean at 2 major research universities. He was founder and Chairman of the Alliance for Animal Genome Research. He is on Board of Industrial Section of BIO.

Luke Li

Dr. Luke Li has 30 years of experience in biopharma and healthcare business. Currently, Dr. Li is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform. Before joining ABG, Dr. Li has held Executive positions at Pfizer and Amgen. He was an Assistant Professor in Medicine at Washington University Medical School.

Jason Wen

Jason Wen is the Director of Technology Transfer at Boston College. He has a broad background combining experience in the life sciences, business, and patent law. Dr. Wen is a long time member of the Association of University Technology Managers (AUTM) and the Licensing Executives Society (LES). He is also a Registered Technology Transfer Professional (RTTP) and a United States Patent and Trademark Office Registered Patent Agent.

Michael Draper

Sanofi North America’s Head of External Science and Partnering on East Coast.

Other judges include delegates from BioSciKin

BioSciKin is actively seeking investment opportunities in precision medicine filed and has made more than 10 investments over past two years in US, Korea and China, with typically investment size ranging from 0.5 million to 10 million USD. 

Organized by: Chinese American Biopharmaceutical Society (CABS) and Association of Chinese Students and Scholars at Stanford (ACSSS); supporting organization: California Life Sciences Institute (CLSI)

Sponsored by: Simcere Pharmaceutical Group; BioSciKin; Simcere State Key Laboratory of Translational Medicine and Innovative Drug R&D; HEALTHCARE EXECUTIVE Magazine; Firestone Investing

About Simcere Simcere is an emerging leader in developing, manufacturing and marketing of innovative medicines and branded generics in China. Simcere was the first Chinese chemical and biological drug company to list on the NYSE in 2007. In 2013, the company went private for strategic considerations. In 2015, Simcere’s translational medicine and innovative drug R&D platform has been recognized as a State Key Laboratory by the National Ministry of Science and Technology. The company has been actively pursuing cross-border partnerships to bringing global innovation to China. In Boston and New Jersey, Simcere has two offices in the US for accelerating international business development.

About BioSciKin BioSciKin (BSK) is an open platform in China for life science entrepreneurs and innovators. Focuses on three major healthcare areas: novel therapeutics, medical devices and mobile healthcare services, BSK is looking for partnership from all over the world for co-development of innovative approaches in precision medicine. In Nanjing, Shanghai and Tianjin, BSK has established 3 R&D-oriented incubation parks with advanced R&D facilities to provide entrepreneurs with customized service and support packages. For more information, please go to BSK’s official website:  You can also email to Ms. Ray Zhang, Senior BD director, BioSciKin (

About HEALTHCARE EXECUTIVE Magazine HEALTHCARE EXECUTIVE Magazine is an influential magazine in the Chinese healthcare industry. 

About Firestone Firestone focuses on innovation and entrepreneurship services in healthcare industry.  

Chinese Investors Looking for Future Unicorns- startup competition in life science – $0 (USD)